Integrating human pluripotent stem cells into drug development

Cell Stem Cell

Volumn 12, Issue 6, 2013, Pages 669-677

  Engle, Sandra J ^a   Puppala, Dinesh ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CELL REGENERATION; COST EFFECTIVENESS ANALYSIS; DEVELOPMENTAL BIOLOGY; DRUG DEVELOPMENT; DRUG INDUSTRY; EMBRYONIC STEM CELL; GENE EXPRESSION; HEART MUSCLE CELL; HUMAN; IN VITRO STUDY; LIVER CELL; NERVE CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL;

EID: 84878878364     PISSN: 19345909     EISSN: 18759777     Source Type: Journal    
DOI: 10.1016/j.stem.2013.05.011     Document Type: Review

References (70)

1. M.J. Allen, M.L. Powers, K.S. Gronowski, and A.M. Gronowski Human tissue ownership and use in research: what laboratorians and researchers should know Clin. Chem. 56 2010 1675 1682
2. American Diabetes Association Economic costs of diabetes in the U.S. in 2012 Diabetes Care 36 2013 1033 1046
3. W.F. An, and N. Tolliday Cell-based assays for high-throughput screening Mol. Biotechnol. 45 2010 180 186
4. M. Baker Testing time for stem cells Nature 463 2010 719
5. J. Besnard, G.F. Ruda, V. Setola, K. Abecassis, R.M. Rodriguiz, X.P. Huang, S. Norval, M.F. Sassano, A.I. Shin, and L.A. Webster Automated design of ligands to polypharmacological profiles Nature 492 2012 215 220
6. A. Campbell, and G. Nycum Harmonizing the international regulation of embryonic stem cell research: possibilities, promises and potential pitfalls Med. Law Int. 7 2005 113 148
7. G.G. Cezar Can human embryonic stem cells contribute to the discovery of safer and more effective drugs? Curr. Opin. Chem. Biol. 11 2007 405 409
8. S.M. Chambers, C.A. Fasano, E.P. Papapetrou, M. Tomishima, M. Sadelain, and L. Studer Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling Nat. Biotechnol. 27 2009 275 280
9. S.Y. Chan, and J. Loscalzo The emerging paradigm of network medicine in the study of human disease Circ. Res. 111 2012 359 374
10. L.T. Cheng, L.T. Sun, and T. Tada Genome editing in induced pluripotent stem cells Genes Cells 17 2012 431 438
11. M. Czepiel, V. Balasubramaniyan, W. Schaafsma, M. Stancic, H. Mikkers, C. Huisman, E. Boddeke, and S. Copray Differentiation of induced pluripotent stem cells into functional oligodendrocytes Glia 59 2011 882 892
12. E. De Trizio, and C.S. Brennan The business of human embryonic stem cell research and an international analysis of relevant laws J. Biolaw Bus. 7 2004 14 22
13. M. Dolsten, and M. Søgaard Precision medicine: an approach to R&D for delivering superior medicines to patients Clin Transl Med 1 2012 7
14. U.S. Eggert The why and how of phenotypic small-molecule screens Nat. Chem. Biol. 9 2013 206 209
15. R. Eglen, and T. Reisine Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening Assay Drug Dev. Technol. 9 2011 108 124
16. R.M. Eglen, A. Gilchrist, and T. Reisine The use of immortalized cell lines in GPCR screening: the good, bad and ugly Comb. Chem. High Throughput Screen. 11 2008 560 565
17. E.S. Fakunle, and J.F. Loring Ethnically diverse pluripotent stem cells for drug development Trends Mol. Med. 18 2012 709 716
18. N. Fusaki, H. Ban, A. Nishiyama, K. Saeki, and M. Hasegawa Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 85 2009 348 362
19. L. Garbes, L. Heesen, I. Hölker, T. Bauer, J. Schreml, K. Zimmermann, M. Thoenes, M. Walter, J. Dimos, and M. Peitz VPA response in SMA is suppressed by the fatty acid translocase CD36 Hum. Mol. Genet. 22 2013 398 407
20. B.P. Georgieva, and J.M. Love Human induced pluripotent stem cells: a review of the US patent landscape Regen. Med. 5 2010 581 591
21. G.K. Gittes Developmental biology of the pancreas: a comprehensive review Dev. Biol. 326 2009 4 35
22. S. Goldbard Bringing primary cells to mainstream drug development and drug testing Curr. Opin. Drug Discov. Devel. 9 2006 110 116
23. E. Goldin, W. Zheng, O. Motabar, N. Southall, J.H. Choi, J. Marugan, C.P. Austin, and E. Sidransky High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase PLoS ONE 7 2012 e29861
24. R. Greek, and M.J. Rice Animal models and conserved processes Theor. Biol. Med. Model. 9 2012 40
25. C. Gulbrandsen WARF's licensing policy for ES cell lines Nat. Biotechnol. 25 2007 387 388
26. Y. Hart, Y.E. Antebi, A.E. Mayo, N. Friedman, and U. Alon Design principles of cell circuits with paradoxical components Proc. Natl. Acad. Sci. USA 109 2012 8346 8351
27. A. Knight Animal experiments scrutinised: systematic reviews demonstrate poor human clinical and toxicological utility ALTEX 24 2007 320 325
28. K.E. Lasser, P.D. Allen, S.J. Woolhandler, D.U. Himmelstein, S.M. Wolfe, and D.H. Bor Timing of new black box warnings and withdrawals for prescription medications JAMA 287 2002 2215 2220
29. D. Leonard-Barton, and W.A. Kraus Implementing new technology Harv. Bus. Rev. November-December 1985 102 109
30. A.D. Levine Access to human embryonic stem cell lines Nat. Biotechnol. 29 2011 1079 1081
31. X. Lian, J. Zhang, S.M. Azarin, K. Zhu, L.B. Hazeltine, X. Bao, C. Hsiao, T.J. Kamp, and S.P. Palecek Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions Nat. Protoc. 8 2013 162 175
32. P. Liang, F. Lan, A.S. Lee, T. Gong, V. Sanchez-Freire, Y. Wang, S. Diecke, K. Sallam, J.W. Knowles, and P.J. Wang Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity Circulation 127 2013 1677 1691
33. A.P. Lodge, C.J. Langmead, G. Daniel, G.W. Anderson, and T.D. Werry Performance of mouse neural stem cells as a screening reagent: characterization of PAC1 activity in medium-throughput functional assays J. Biomol. Screen. 15 2010 159 168
34. J. Lowenthal, S. Lipnick, M. Rao, and S.C. Hull Specimen collection for induced pluripotent stem cell research: harmonizing the approach to informed consent Stem Cells Transl Med 1 2012 409 421
35. R. Macarron, M.N. Banks, D. Bojanic, D.J. Burns, D.A. Cirovic, T. Garyantes, D.V. Green, R.P. Hertzberg, W.P. Janzen, and J.W. Paslay Impact of high-throughput screening in biomedical research Nat. Rev. Drug Discov. 10 2011 188 195
36. L.N. Makley, and J.E. Gestwicki Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions Chem. Biol. Drug Des. 81 2013 22 32
37. F.T. Merkle, and K. Eggan Modeling human disease with pluripotent stem cells: from genome association to function Cell Stem Cell 12 2013 656 668 this issue
38. B.H. Munos, and W.W. Chin A call for sharing: adapting pharmaceutical research to new realities Sci. Transl. Med. 1 2009 cm8
39. C.R. Nicholas, J. Chen, Y. Tang, D.G. Southwell, N. Chalmers, D. Vogt, C.M. Arnold, Y.J. Chen, E.G. Stanley, and A.G. Elefanty Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development Cell Stem Cell 12 2013 573 586
40. G.P. Nolan What's wrong with drug screening today Nat. Chem. Biol. 3 2007 187 191
41. J. Olesen, A. Gustavsson, M. Svensson, H.U. Wittchen, B. Jönsson CDBE2010 study group European Brain CouncilCDBE2010 Study GroupEuropean Brain Council The economic cost of brain disorders in Europe Eur. J. Neurol. 19 2012 155 162
42. S.P. Paşca, T. Portmann, I. Voineagu, M. Yazawa, A. Shcheglovitov, A.M. Paşca, B. Cord, T.D. Palmer, S. Chikahisa, and S. Nishino Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome Nat. Med. 17 2011 1657 1662
43. PCAST. (2008). Priorities for personalized medicine. Report of the President's Council of Advisors on Science and Technology. September 2008. http://www.whitehouse.gov/files/documents/ostp/PCAST/pcast-report-v2.pdf.
44. D. Puppala, L.P. Collis, S.Z. Sun, V. Bonato, X. Chen, B. Anson, M. Pletcher, B. Fermini, and S.J. Engle Comparative gene expression profiling in human-induced pluripotent stem cell - derived cardiocytes and human and cynomolgus heart tissue Toxicol. Sci. 131 2013 292 301
45. M. Rao Public private partnerships: a marriage of necessity Cell Stem Cell 12 2013 149 151
46. R.K. Rowntree, and J.D. McNeish Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery Regen. Med. 5 2010 557 568
47. J. Sahi, S. Grepper, and C. Smith Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery Curr. Drug Discov. Technol. 7 2010 188 198
48. F. Sams-Dodd Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift Drug Discov. Today 18 2013 211 217
49. G. Sandusky, C. Dumaual, and L. Cheng Review paper: human tissues for discovery biomarker pharmaceutical research: the experience of the Indiana University Simon Cancer Center-Lilly Research Labs Tissue/Fluid BioBank Vet. Pathol. 46 2009 2 9
50. P. Sartipy, P. Björquist, R. Strehl, and J. Hyllner The application of human embryonic stem cell technologies to drug discovery Drug Discov. Today 12 2007 688 699
51. J.W. Scannell, A. Blanckley, H. Boldon, and B. Warrington Diagnosing the decline in pharmaceutical R&D efficiency Nat. Rev. Drug Discov. 11 2012 191 200
52. D. Schuster, C. Laggner, and T. Langer Why drugs fail - a study on side effects in new chemical entities Curr. Pharm. Des. 11 2005 3545 3559
53. K. Si-Tayeb, F.P. Lemaigre, and S.A. Duncan Organogenesis and development of the liver Dev. Cell 18 2010 175 189
54. Z. Song, J. Cai, Y. Liu, D. Zhao, J. Yong, S. Duo, X. Song, Y. Guo, Y. Zhao, and H. Qin Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells Cell Res. 19 2009 1233 1242
55. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
56. K. Takahashi, K. Okita, M. Nakagawa, and S. Yamanaka Induction of pluripotent stem cells from fibroblast cultures Nat. Protoc. 2 2007 3081 3089
57. K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, and S. Yamanaka Induction of pluripotent stem cells from adult human fibroblasts by defined factors Cell 131 2007 861 872
58. J.A. Thomson, J. Itskovitz-Eldor, S.S. Shapiro, M.A. Waknitz, J.J. Swiergiel, V.S. Marshall, and J.M. Jones Embryonic stem cell lines derived from human blastocysts Science 282 1998 1145 1147
59. S. Tohyama, F. Hattori, M. Sano, T. Hishiki, Y. Nagahata, T. Matsuura, H. Hashimoto, T. Suzuki, H. Yamashita, and Y. Satoh Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes Cell Stem Cell 12 2013 127 137
60. H.B. van der Worp, D.W. Howells, E.S. Sena, M.J. Porritt, S. Rewell, V. O'Collins, and M.R. Macleod Can animal models of disease reliably inform human studies? PLoS Med. 7 2010 e1000245
61. P. Van Vliet, S.M. Wu, S. Zaffran, and M. Pucéat Early cardiac development: a view from stem cells to embryos Cardiovasc. Res. 96 2012 352 362
62. R. Vidal, F. Pilar-Cuéllar, S. dos Anjos, R. Linge, B. Treceño, V.I. Vargas, A. Rodriguez-Gaztelumendi, R. Mostany, E. Castro, and A. Diaz New strategies in the development of antidepressants: towards the modulation of neuroplasticity pathways Curr. Pharm. Des. 17 2011 521 533
63. C. Vieira, A. Pombero, R. García-Lopez, L. Gimeno, D. Echevarria, and S. Martínez Molecular mechanisms controlling brain development: an overview of neuroepithelial secondary organizers Int. J. Dev. Biol. 54 2010 7 20
64. L. Warren, P.D. Manos, T. Ahfeldt, Y.H. Loh, H. Li, F. Lau, W. Ebina, P.K. Mandal, Z.D. Smith, and A. Meissner Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA Cell Stem Cell 7 2010 618 630
65. Y.M. Yang, S.K. Gupta, K.J. Kim, B.E. Powers, A. Cerqueira, B.J. Wainger, H.D. Ngo, K.A. Rosowski, P.A. Schein, and C.A. Ackeifi A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS Cell Stem Cell 2013 10.1016/j.stem.2013.04.003 Published online April 18, 2013
66. M. Yazawa, B. Hsueh, X. Jia, A.M. Pasca, J.A. Bernstein, J. Hallmayer, and R.E. Dolmetsch Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome Nature 471 2011 230 234
67. P. Yi, J.S. Park, and D.A. Melton Betatrophin: a hormone that controls pancreatic β cell proliferation Cell 153 2013 747 758
68. J. Yu, M.A. Vodyanik, K. Smuga-Otto, J. Antosiewicz-Bourget, J.L. Frane, S. Tian, J. Nie, G.A. Jonsdottir, V. Ruotti, and R. Stewart Induced pluripotent stem cell lines derived from human somatic cells Science 318 2007 1917 1920
69. J. Yu, K. Hu, K. Smuga-Otto, S. Tian, R. Stewart, I.I. Slukvin, and J.A. Thomson Human induced pluripotent stem cells free of vector and transgene sequences Science 324 2009 797 801
70. D. Zhang, W. Jiang, M. Liu, X. Sui, X. Yin, S. Chen, Y. Shi, and H. Deng Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells Cell Res. 19 2009 429 438